In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 8, 2002, Pages 2595-2601

  Petersen, Peter J ^a   Bradford, Patricia A ^a   Weiss, William J ^a   Murphy, Timothy M ^a   Sum, P E ^a   Projan, Steven J ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CALCIUM; DAPTOMYCIN; ERYTHROMYCIN; GLYCOPEPTIDE; LEVOFLOXACIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN; DRUG DERIVATIVE; MINOCYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; ENTEROCOCCUS; FEMALE; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PENICILLIN RESISTANCE; PHENOTYPE;

ANIMAL; ANTIBIOTICS, GLYCOPEPTIDE; ANTIBIOTICS, PEPTIDE; CALCIUM; COMPARATIVE STUDY; DAPTOMYCIN; FEMALE; GRAM-POSITIVE BACTERIA; METHICILLIN RESISTANCE; MICE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PHENOTYPE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; ANIMALS; ANTI-BACTERIAL AGENTS;

EID: 0035991964     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.8.2595-2601.2002     Document Type: Article

References (40)

1. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032
2. Antimicrobial resistance in gram-positive pathogens isolated in the UK between October 1996 and January 1997
3. Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate
4. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections
5. Recent developments in macrolides and ketolides
6. Recent progress in novel macrolides, quinolones, and 2-pyridones to overcome bacterial resistance
7. Evaluation of new antimicrobials in vitro and in experimental animal infections
8. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin
9. Oxazolidinones: A review
10. Identification of Enterococcus species isolated from human infections by a conventional test scheme
11. Linezolid
12. Linezolid: An oxazolidinone antimicrobial agent
13. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates
14. In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates
15. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
16. Linezolid and reversible myelosuppression
17. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin
18. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: The role of streptogramins and other newer compounds
19. A new channel-forming antibiotic from Streptomyces coelicolor A3(2) which requires calcium for its activity
20. The lipopeptide antibiotic A21978C has a specific interaction with DMPC only in the presence of calcium ions
21. Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes
22. Quinupristin/dalfopristin: A review of its use in the management of serious gram-positive infections
23. Control of multiple-resistant bacteria
24. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against positive bacteria
25. Once-daily dosing in dogs optimizes daptomycin safety
26. Current and future management of infections due to methicillin-resistant staphylococci infections: The role of quinupristin/dalfopristin
27. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)
28. Survey of blood stream infections attributable to gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program
29. Preclinical pharmacology of GAR-936, a novel glycylcyline antibacterial agent
30. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia
31. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains
32. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens
33. Susceptibility tests: Special tests
34. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936
35. Daptomycin: A novel agent for gram-positive infections
36. Implications of vancomycin-resistant Staphylococcus aureus
37. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines
38. In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study